Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients
2002 | journal article
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Jacob S, Poeggeler B, Weishaupt JH, Sirén, Anna-Leena, Hardeland R, Bähr M, et al. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. Journal of Pineal Research. 2002;33(3):186-187. doi:10.1034/j.1600-079X.2002.02943.x.
